Dasatinib first-line: Multicentric Italian experience outside clinical trials

Massimo Breccia, Fabio Stagno, Luigiana Luciano, Elisabetta Abruzzese, Mario Annunziata, Mariella D'Adda, Alessandro Maggi, Nicola Sgherza, Antonella Russo-Rossi, Patrizia Pregno, Fausto Castagnetti, Alessandra Iurlo, Roberto Latagliata, Michele Cedrone, Nicola Di Renzo, Federica Sorà, Giovanna Rege-Cambrin, Giorgio La Nasa, Anna Rita Scortechini, Giovanna GrecoLuca Franceschini, Simona Sica, Monica Bocchia, Monica Crugnola, Esther Orlandi, Attilio Guarini, Giorgina Specchia, Gianantonio Rosti, Giuseppe Saglio, Giuliana Alimena

Research output: Contribution to journalArticlepeer-review


Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treatment outside clinical trials. One hundred and nine patients (median age 54 years) were treated from January 2012 to December 2013. Increased incidence of high risk patients were detected according to stratification (26% according to Sokal score, 19% according to Euro score and 16% according to EUTOS) when compared to company sponsored studies. Median time from diagnosis to start of dasatinib was 18 days. Ten patients received unscheduled starting dose (6 patients 50. mg and 4 patients 80. mg QD), whereas 99 patients started with 100. mg QD. At 3 months, 92% of patients achieved a BCR-ABL ratio less than 10%. At 6 months, the rate of CCyR was 91% and the rate of MR3 was 40%, with 8% of the patients reaching MR4.5. Ninety-three patients were evaluable at 12 months: the rate of MR3 was 62%, with MR4.5 being achieved by 19% of the patients. At a median follow-up of 12 months, 27 patients (24.7%) were receiving the drug at reduced dose. Two patients (1.8%) experienced a lymphoid blast crisis and the overall incidence of resistance was 8%. As regards safety, the major side effects recorded were thrombocytopenia, neutropenia and pleural effusions, which occurred in 22%, 10% and 8% of patients, respectively. Present results, achieved in a large cohort of patients treated outside clinical trials, further confirm the efficacy and safety of dasatinib as firstline treatment in CML.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalLeukemia Research
Publication statusPublished - 2016


  • Chronic myeloid leukemia
  • Dasatinib
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Dasatinib first-line: Multicentric Italian experience outside clinical trials'. Together they form a unique fingerprint.

Cite this